More Noxopharm Ltd. news
Noxopharm Ltd.ASX: NOX

NYX-104 delivers Key Proof-of-Concept in Stroke Animal Model

Nov 28, 2017 at 10:06 PM EST · Issued by Noxopharm Ltd.

Filed with ASX · Nov 28, 2017 at 10:06 PM EST · 3 pages · English

On 6ix: 6ix.com/news/nyx-104-delivers-key-proof-of-concept-in-stroke-animal-model

Noxopharm Ltd. on 6ix

Earlier from Noxopharm

  • Clarification of Incorrect InformationNov 23, 2017
  • Promising Interim Clinical Data for NOX66Nov 19, 2017
  • 1st Patient treated in Lupin Study at St Vincents HospitalNov 15, 2017
  • UNSW collaboration confirms drug designed for stroke victimsNov 2, 2017
  • Australian NOX66 - Radiotherapy Study OpensSep 26, 2017

Later from Noxopharm

  • Nyrada Inc Opens Capital Raise - Memorandum ReleasedNov 30, 2017
  • EOY Guidance on 2018 NOX66 Clinical Development StrategyDec 21, 2017
  • NOX receives FY17 R&D Tax RebateJan 17, 2018
  • NOX closes $4m capital raising for US subsidiary Nyrada IncFeb 15, 2018
  • Appendix 4D and Half Year AccountsFeb 22, 2018
All Noxopharm news releases↗

Follow Noxopharm into a list and get an email when it puts out news.

Follow Noxopharm
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer